<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05125068</url>
  </required_header>
  <id_info>
    <org_study_id>AT-1501-N205</org_study_id>
    <nct_id>NCT05125068</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)</brief_title>
  <official_title>A Phase 2a, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eledon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eledon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2a, multicenter, open-label study designed to evaluate the safety and&#xD;
      efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of&#xD;
      protein in their urine at the time of screening.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of&#xD;
      AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of protein in their&#xD;
      urine at the time of Screening. Up to 42 eligible patients will receive one of 2 doses of&#xD;
      AT-1501. All patients are scheduled to receive AT-1501 by intravenous infusion every 3 weeks&#xD;
      for approximately 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy - change in participants UPCR</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The change in 24-hour urine protein to creatinine ratio (UPCR) from baseline to 24 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety- Number of participants with treatment related adverse events</measure>
    <time_frame>Through study completion, an average of 100 weeks</time_frame>
    <description>Incidence of serious adverse events (SAEs), treatment-emergent adverse events (TEAEs), and AEs of special interest (AEoSI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in eGFR slope</measure>
    <time_frame>Baseline- 96 weeks</time_frame>
    <description>The change in eGFR slope from baseline to 96 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urine protein excretion (mg/mg)</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>The change in urine protein excretion over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Anti drug Antibodies (ADAs)</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>The percentage of participants who develop ADAs</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory- Change in baseline serum biomarkers</measure>
    <time_frame>Through study completion, an average of 100 weeks</time_frame>
    <description>The change in serum biomarkers from baseline to completion of study</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>IgA Nephropathy</condition>
  <condition>IgAN</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AT-1501 10mg/kg Arm A will receive 10 mg/kg of AT-1501 every 3 weeks for up to 93 weeks for a total of 32 infusions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AT-1501 5mg/kg Arm B will receive 5 mg/kg of AT-1501 every 3 weeks for up to 93 weeks for a total of 32 infusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-1501</intervention_name>
    <description>AT-1501 monoclonal antibody targeting CD40L given as an IV infusion</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female ≥ 18 years of age&#xD;
&#xD;
          2. Biopsy proven IgAN&#xD;
&#xD;
          3. Urine protein ≥ 0.75g/24 hours at Screening despite optimization with ACE inhibitors&#xD;
             or angiotensin receptor blockers (ARB)&#xD;
&#xD;
          4. eGFR ≥ 45 mL/min per 1.73 m2 or eGFR &lt; 45 mL/min per 1.73 m2 and ≥ 30 mL/min per 1.73&#xD;
             m2 with a kidney biopsy within 2 years of Screening showing &lt; 50% tubulointerstitial&#xD;
             fibrosis&#xD;
&#xD;
          5. Agree to comply with contraception requirements during and for 90 days after study&#xD;
             completion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any secondary IgAN as defined by the investigator&#xD;
&#xD;
          2. Patients who have undergone a kidney transplant&#xD;
&#xD;
          3. Any history of kidney disease other than IgAN&#xD;
&#xD;
          4. Any history of diabetes (Type 1 or Type 2)&#xD;
&#xD;
          5. Seated blood pressure &gt; 140 mmHg (systolic) or &gt; 90 mmHg (diastolic) at the Screening&#xD;
             Visit. Patients must be on a stable dose and regimen of an ACE inhibitor or ARB for at&#xD;
             least 90 days&#xD;
&#xD;
          6. Pregnancy or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Bornstein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Eledon Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Bartoshevich</last_name>
    <phone>949-238-8090</phone>
    <email>jbartoshevich@eledon.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IgA Nephropathy</keyword>
  <keyword>IgAN</keyword>
  <keyword>AT-1501</keyword>
  <keyword>CD40L</keyword>
  <keyword>Monoclonal antibody</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>eGFR</keyword>
  <keyword>UPCR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

